Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SGEN Seagen Inc

0.00 (0.00%)
May 23 2024 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 0
Bid Price 228.74
Ask Price 228.74
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
Seagen Inc SGEN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 228.74 20:00:00
Open Price Low Price High Price Close Price Prev Close
228.74 228.74
Trades Volume Avg Volume 52 Week Range
0 0 - 190.67 - 228.96
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 228.74 USD

Seagen Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 43.15B - - - -237.39
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Seagen News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No SGEN Message Board. Create One! See More Posts on SGEN Message Board See More Message Board Posts

Historical SGEN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.
3 Months0.
6 Months213.27228.96212.44225.073,287,89715.477.25%
1 Year197.27228.96190.67209.261,470,81531.4715.95%
3 Years154.93228.96105.43171.711,170,78673.8147.64%
5 Years68.41228.9663.02156.171,120,501160.33234.37%

Seagen Description

Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.

Your Recent History

Delayed Upgrade Clock